TR200201150T2 - Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod. - Google Patents

Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.

Info

Publication number
TR200201150T2
TR200201150T2 TR2002/01150T TR200201150T TR200201150T2 TR 200201150 T2 TR200201150 T2 TR 200201150T2 TR 2002/01150 T TR2002/01150 T TR 2002/01150T TR 200201150 T TR200201150 T TR 200201150T TR 200201150 T2 TR200201150 T2 TR 200201150T2
Authority
TR
Turkey
Prior art keywords
inhibitor
phosphodiesterase
administering
rate
administered
Prior art date
Application number
TR2002/01150T
Other languages
English (en)
Inventor
D. Murdoch Robert
J. Torphy Theodore
D. Zussman Barry
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of TR200201150T2 publication Critical patent/TR200201150T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Bu bulus, tek bir defada uygulanabilen ve inhibitörün plazma konsantrasyonunda yükselme hizini veya abzorpsiyon hizini düsürmek suretiyle hasta tarafindan iyi tolere edilebilen, bir PDE4 inhibitörü dozunun yükseltilmesine yönelik bir metod ile ilgilidir.
TR2002/01150T 1999-10-29 2000-10-26 Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod. TR200201150T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
TR200201150T2 true TR200201150T2 (tr) 2002-09-23

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01150T TR200201150T2 (tr) 1999-10-29 2000-10-26 Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.

Country Status (29)

Country Link
US (1) US20030212112A1 (tr)
EP (1) EP1225884A4 (tr)
JP (1) JP2003513038A (tr)
KR (1) KR20020050249A (tr)
CN (1) CN1387433A (tr)
AP (1) AP2002002446A0 (tr)
AR (1) AR026254A1 (tr)
AU (1) AU772909B2 (tr)
BG (1) BG106623A (tr)
BR (1) BR0015039A (tr)
CA (1) CA2389293A1 (tr)
CO (1) CO5271676A1 (tr)
CZ (1) CZ20021443A3 (tr)
DZ (1) DZ3249A1 (tr)
EA (1) EA200200502A1 (tr)
HK (1) HK1049105A1 (tr)
HU (1) HUP0203682A3 (tr)
IL (1) IL148813A0 (tr)
MA (1) MA25562A1 (tr)
MX (1) MXPA02004220A (tr)
NO (1) NO20021937L (tr)
NZ (1) NZ518002A (tr)
OA (1) OA12078A (tr)
PE (1) PE20011004A1 (tr)
PL (1) PL355262A1 (tr)
SK (1) SK7292002A3 (tr)
TR (1) TR200201150T2 (tr)
UY (1) UY26422A1 (tr)
WO (1) WO2001032165A1 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
ME00565A (en) * 2002-05-28 2011-12-20 Topically applicable pharmaceutical preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
RS20050669A (en) 2003-03-10 2008-04-04 Altana Pharma Ag., Novel process for the preparation of roflumilast
WO2004096274A1 (ja) * 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. 気道内投与剤
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2006097456A1 (en) 2005-03-16 2006-09-21 Nycomed Gmbh Taste masked dosage form containing roflumilast
MX2012006265A (es) * 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
KR20210033073A (ko) * 2011-12-27 2021-03-25 암젠 (유럽) 게엠베하 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
CO5271676A1 (es) 2003-04-30
EP1225884A4 (en) 2005-06-15
AU1344501A (en) 2001-05-14
AU772909B2 (en) 2004-05-13
HK1049105A1 (zh) 2003-05-02
MA25562A1 (fr) 2002-10-01
NO20021937D0 (no) 2002-04-24
IL148813A0 (en) 2002-09-12
EA200200502A1 (ru) 2002-10-31
MXPA02004220A (es) 2002-10-17
AP2002002446A0 (en) 2002-03-31
HUP0203682A3 (en) 2003-10-28
WO2001032165A1 (en) 2001-05-10
SK7292002A3 (en) 2002-12-03
OA12078A (en) 2003-05-28
BR0015039A (pt) 2002-06-25
UY26422A1 (es) 2001-07-31
CN1387433A (zh) 2002-12-25
HUP0203682A2 (hu) 2003-04-28
BG106623A (bg) 2003-02-28
JP2003513038A (ja) 2003-04-08
NO20021937L (no) 2002-05-30
DZ3249A1 (fr) 2001-05-10
NZ518002A (en) 2004-01-30
CA2389293A1 (en) 2001-05-10
PL355262A1 (en) 2004-04-05
US20030212112A1 (en) 2003-11-13
AR026254A1 (es) 2003-02-05
KR20020050249A (ko) 2002-06-26
EP1225884A1 (en) 2002-07-31
PE20011004A1 (es) 2001-09-28
CZ20021443A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
TR200201150T2 (tr) Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
DE69618231T2 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
MXPA02010316A (es) Terapia novedosa para los trastornos asociados con la hiperlipidemia.
BR9808221A (pt) Método de tratamento de tumor.
DE69821498D1 (de) Verwendung von amifostin
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
SE0004827D0 (sv) Therapeutic compounds
TR200202033T2 (tr) Epilepsi Tedavisi İçin Terkipler ve Yöntemler
DK1244442T3 (da) Fremgangsmåde til bestemmelse af nukleotidsynteseinhibitorer med færre bivirkninger
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
WO2003066806A3 (en) Therapeutic use of aziridino compounds